CPRX - CATALYST PHARMACEUTICALS, INC.
IEX Last Trade
21.81
0.015 0.069%
Share volume: 12,244
Last Updated: Thu 26 Dec 2024 08:29:42 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$21.80
0.01
0.07%
Fundamental analysis
56%
Profitability
74%
Dept financing
4%
Liquidity
66%
Performance
49%
Performance
5 Days
0.09%
1 Month
-1.41%
3 Months
8.37%
6 Months
43.37%
1 Year
26.14%
2 Year
13.73%
Key data
Stock price
$21.81
DAY RANGE
$21.49 - $21.84
52 WEEK RANGE
$13.50 - $24.27
52 WEEK CHANGE
$25.70
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Patrick J. McEnany
Region: US
Website: catalystpharma.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: catalystpharma.com
Employees: 80
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Catalyst Pharmaceuticals, Inc. focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and Ruzurgi.
Recent news